Navigation Links
Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore

COLUMBUS, Ohio, Jan. 19 /PRNewswire-FirstCall/ -- Abbott Nutrition today announced that it is initiating a precautionary, voluntary recall of ZonePerfect(R) Chocolate Peanut Butter bars, ZonePerfect(R) Peanut Toffee bars and NutriPals(TM) Peanut Butter Chocolate bars in response to the widening recall involving peanut butter and peanut paste ingredients manufactured by Peanut Corporation of America (PCA). PCA was one of the peanut ingredient suppliers to the company.

The specified Abbott Nutrition items, sold in the U.S. and internationally (Mexico, New Zealand and Singapore) in various packages and quantities, have not been linked to a nationwide salmonella outbreak and there have been no reported cases of the salmonella illness associated with ZonePerfect or NutriPals products. Abbott Nutrition tests every lot of finished ZonePerfect and NutriPals bars for salmonella and no salmonella contamination has been detected. This voluntary recall does not apply to Abbott Nutrition products sold in Canada.

Abbott Nutrition's action to issue a voluntary recall was supported by the U.S. Food & Drug Administration's advisement to manufacturers of an ongoing outbreak of salmonella involving peanut butter and peanut paste supplied by PCA. No other Abbott Nutrition products have been impacted by the PCA recall.

As part of its priority to ensure the safety and quality of all of its products, Abbott is issuing the voluntary recall. Abbott is working with retail partners to remove the specified products from retail store shelves and encouraging customers and consumers to verify if they have the specified products.

Consumers who have purchased the recalled products are urged to destroy the product. U.S. consumers with questions or who would like a refund may contact Abbott Nutrition Consumer Relations at (800) 986-8884, Monday through Friday, between the hours of 8:30 a.m. and 5:00 p.m. Eastern Time. Consumers with questions or concerns about their health should contact their doctor.

    Products impacted by the voluntary withdrawal are as follows:

    * ZonePerfect Chocolate Peanut Butter bars, all sizes and quantities
    * ZonePerfect Peanut Toffee bars, all sizes and quantities
    * NutriPals Peanut Butter Chocolate nutrition bars, all sizes and

    For images of these products, please visit the following link:

Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. For more information on Salmonella, please visit the Centers for Disease Control and Prevention's Website at

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety of ... and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ . ... WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during treatment ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... November 25, 2015 --> ... sie eine Lizenz für das Patent über eine neue ... und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... ins Leben gerufenen und von Edelris gemeinsam mit seinen ... ein Behandlungsziel für HBV identifiziert, und es wurden neue ...
Breaking Medicine Technology: